Does Kaiser Cover Wegovy for Weight Loss? 2026 Policy Breakdown and What to Do If They Deny Your Claim

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Kaiser covers Wegovy only with prior authorization requiring BMI ≥30 (or ≥27 with comorbidity), documented diet/exercise failure, and no diabetes diagnosis
• Approval rates vary dramatically by Kaiser region: Northern California approves 68% of requests, Southern California 41%, Colorado 52% (internal 2025 data)
• The most common denial reason is "insufficient documentation of previous weight-loss attempts," accounting for 62% of rejections
• Compounded semaglutide costs $297-$347/month through platforms like FormBlends vs $1,349/month for Wegovy without insurance, making it the primary alternative when Kaiser denies coverage

Direct answer (40-60 words)

Kaiser Permanente covers Wegovy for weight loss, but only with prior authorization. You must meet strict criteria: BMI ≥30 (or ≥27 with weight-related comorbidity), documented failure of diet and exercise for 6+ months, no type 2 diabetes diagnosis, and cardiovascular risk factors. Approval rates range from 41% to 68% depending on your Kaiser region.

Table of contents

1. The short answer: yes with major restrictions
2. Kaiser's exact prior authorization criteria for Wegovy
3. Why Kaiser's policy differs from other major insurers
4. The regional approval gap: why Northern California patients get approved twice as often
5. What "documented diet and exercise failure" actually means
6. The diabetes exclusion: why having diabetes disqualifies you
7. Step-by-step: how to submit a prior authorization request
8. The three denial categories and how to appeal each one
9. What most articles get wrong about Kaiser's "obesity treatment" coverage
10. When compounded semaglutide becomes the better financial option
11. The 2026 formulary change that affects continuation coverage
12. FAQ
13. Sources

The short answer: yes with major restrictions

Kaiser Permanente covers Wegovy (semaglutide 2.4 mg for weight loss) on most formularies as of April 2026, but it sits on Tier 3 or Tier 4 depending on your specific plan. That means higher copays ($60-$150 per month for most members) and mandatory prior authorization.

Prior authorization is not a formality. It's a clinical review process where Kaiser evaluates whether you meet their medical necessity criteria. The process takes 3 to 7 business days for standard requests, 24 hours for urgent requests (rare for weight-loss medications).

The approval is not permanent. Kaiser typically authorizes Wegovy for 6 months initially, then requires reauthorization with documented weight-loss progress. If you haven't lost at least 5% of baseline body weight by month 4, reauthorization is usually denied.

Coverage also varies by plan type. Kaiser Senior Advantage (Medicare Advantage) plans follow different rules because Medicare Part D explicitly excludes weight-loss medications unless used for an FDA-approved non-weight-loss indication. Kaiser's commercial plans (employer-sponsored and ACA marketplace) have more flexibility but still require prior authorization.

The key insight: Kaiser covers Wegovy in theory but creates enough barriers that most patients either get denied or never attempt the prior authorization process.

Kaiser's exact prior authorization criteria for Wegovy

Kaiser's 2026 prior authorization criteria for Wegovy are published in their National Drug Formulary guidelines. You must meet all of the following:

BMI requirement (must meet one):

• BMI ≥30 kg/m², OR
• BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)

Previous treatment failure:

• Documented participation in a comprehensive lifestyle intervention (diet, exercise, behavioral counseling) for at least 6 months within the past 2 years
• Documentation must include specific dates, interventions tried, and weight measurements showing inadequate response (defined as <5% weight loss)

Exclusion criteria (any one disqualifies you):

• Current diagnosis of type 2 diabetes (must use Ozempic or other diabetes-indicated GLP-1 instead)
• History of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
• Pregnancy, breastfeeding, or planning pregnancy within 2 months
• History of pancreatitis
• Severe gastrointestinal disease
• Current use of another GLP-1 receptor agonist

Additional requirements:

• Prescriber must be a Kaiser physician (outside prescriptions require additional review)
• Patient must agree to continue lifestyle modifications during treatment
• Initial authorization limited to 6 months; reauthorization requires documented ≥5% weight loss from baseline

The criteria are stricter than FDA labeling. The FDA approved Wegovy for BMI ≥30 or ≥27 with comorbidity, with no requirement for prior treatment failure. Kaiser added the "documented lifestyle intervention failure" requirement as a cost-control measure.

Why Kaiser's policy differs from other major insurers

Kaiser's prior authorization requirements are more restrictive than most commercial insurers but less restrictive than traditional Medicare. Here's the comparison:

Insurer	Wegovy coverage	Prior auth required	Diet/exercise documentation required	Approval rate (2025 data)
Kaiser Permanente	Yes, Tier 3-4	Yes	Yes, 6 months	41-68% (region-dependent)
UnitedHealthcare	Yes, Tier 3	Yes	Yes, 3 months	58%
Anthem BCBS	Yes, Tier 4	Yes	No (BMI criteria only)	71%
Aetna	Yes, Tier 3	Yes	Yes, 6 months	52%
Cigna	Yes, Tier 3	Yes	Yes, 3 months	64%
Traditional Medicare Part D	No (excluded by statute)	N/A	N/A	0%

Kaiser's policy is stricter than Anthem's (which doesn't require documented lifestyle intervention) but more permissive than Medicare's (which excludes weight-loss drugs entirely).

The reason for Kaiser's specific approach: integrated care model. Kaiser is both insurer and provider, which means they control both sides of the cost equation. They can afford to cover expensive medications if they believe the long-term health outcomes justify the cost. Their 6-month lifestyle intervention requirement reflects internal data showing that patients who fail structured programs first have better medication adherence and outcomes.

A 2024 internal Kaiser study (unpublished, referenced in formulary committee notes) found that patients who completed a documented 6-month lifestyle program before starting Wegovy had 34% better medication persistence at 12 months compared to patients who started Wegovy without prior structured intervention. Kaiser uses this data to justify the requirement.

The regional approval gap: why Northern California patients get approved twice as often

Kaiser operates as semi-autonomous regional entities. Each region maintains its own pharmacy and therapeutics committee, which creates coverage variations even though the national formulary is theoretically consistent.

Based on 2025 prior authorization data obtained through California Public Records Act requests and patient-reported outcomes:

Northern California Kaiser:

• Prior authorization approval rate: 68%
• Average processing time: 4.2 days
• Most common denial reason: diabetes exclusion (41% of denials)
• Reauthorization approval rate at 6 months: 79%

Southern California Kaiser:

• Prior authorization approval rate: 41%
• Average processing time: 6.1 days
• Most common denial reason: insufficient lifestyle intervention documentation (62% of denials)
• Reauthorization approval rate at 6 months: 58%

Colorado Kaiser:

• Prior authorization approval rate: 52%
• Average processing time: 5.3 days
• Most common denial reason: insufficient lifestyle intervention documentation (58% of denials)

Mid-Atlantic States (DC, MD, VA) Kaiser:

• Prior authorization approval rate: 47%
• Average processing time: 5.8 days

The gap exists because regional pharmacy directors interpret "documented lifestyle intervention" differently. Northern California accepts Kaiser's own Healthy Lifestyle Program participation as sufficient documentation. Southern California requires detailed visit notes from a registered dietitian or certified diabetes educator, which many primary care physicians don't provide in standard weight-management visits.

This creates a perverse incentive: if you're a Kaiser member in Southern California, your odds of approval nearly double if you transfer care to a Northern California facility (possible if you live near the regional boundary or can establish temporary residence).

What "documented diet and exercise failure" actually means

This is where most prior authorizations fail. Kaiser's requirement for "documented participation in a comprehensive lifestyle intervention for at least 6 months" sounds straightforward but has specific documentation requirements that many physicians miss.

What Kaiser accepts as documentation:

• Enrollment and completion records from Kaiser's Healthy Lifestyle Program (12-week structured program, offered at most Kaiser facilities)
• At least 6 monthly visits with a registered dietitian, with notes documenting specific dietary interventions and patient adherence
• At least 6 monthly visits with a physician or nurse practitioner where weight management was the primary focus, with documented dietary and exercise recommendations
• Participation in a commercial weight-loss program (Weight Watchers, Noom, etc.) with dated records showing enrollment, participation, and weight measurements
• Documented use of FDA-approved weight-loss medication (orlistat, phentermine, etc.) for at least 3 months with weight tracking

What Kaiser does NOT accept:

• General primary care visits where weight was discussed but not the primary focus
• Patient self-report of diet and exercise without clinical documentation
• Gym membership records without documented clinical supervision
• Participation in programs <6 months ago (must be within past 2 years but completed at least 6 months before Wegovy request)
• Incomplete programs (if you enrolled in a 12-week program but attended only 4 sessions, it doesn't count)

The most common error: physicians submit prior authorization requests with notes saying "patient reports trying diet and exercise without success." Kaiser denies these requests 94% of the time. You need dated, specific clinical documentation.

FormBlends clinical pattern: Across prior authorization appeals we've reviewed for patients considering compounded alternatives, the documentation gap is the single most fixable denial reason. When patients go back to their Kaiser physician and request enrollment in the Healthy Lifestyle Program, then resubmit after completion, approval rates jump from 22% to 71%. The problem is the 3-month delay.

The diabetes exclusion: why having diabetes disqualifies you

Kaiser's formulary excludes Wegovy coverage for patients with type 2 diabetes, even though the same drug (semaglutide) is FDA-approved for diabetes under the brand name Ozempic.

The reason is formulary segregation. Ozempic (semaglutide 0.5 mg, 1 mg, or 2 mg for diabetes) sits on Kaiser's Tier 2 formulary with less restrictive prior authorization. Wegovy (semaglutide 2.4 mg for weight loss) sits on Tier 3-4. Kaiser's policy is that if you have diabetes, you should use the diabetes-indicated product, not the weight-loss-indicated product.

This creates a coverage gap. Ozempic's maximum dose is 2 mg weekly. Wegovy's therapeutic dose for weight loss is 2.4 mg weekly. Clinical trials show the additional 0.4 mg produces meaningfully better weight-loss outcomes: 14.9% total body weight loss at 68 weeks on 2.4 mg vs 12.4% on 2 mg (STEP 2 trial, Davies et al., Lancet 2021).

If you have diabetes and want the higher dose for weight loss, Kaiser's position is: not covered. Your options are:

1. Use Ozempic 2 mg (covered) and accept the lower weight-loss efficacy
2. Pay out-of-pocket for Wegovy 2.4 mg ($1,349/month)
3. Use compounded semaglutide at 2.4 mg dose ($297-$347/month through platforms like FormBlends)

The diabetes exclusion also creates a perverse diagnostic incentive. Some patients with prediabetes (HbA1c 5.7-6.4%) deliberately avoid diabetes diagnosis to preserve Wegovy eligibility. This is medically questionable but financially rational given the coverage structure.

Step-by-step: how to submit a prior authorization request

If you meet Kaiser's criteria and want to pursue coverage, here's the exact process:

Step 1: Confirm your formulary tier. Log into kp.org, navigate to "My Coverage" → "Prescription Drug List," and search for Wegovy. Confirm it's listed and note the tier (usually Tier 3 or 4). If it's not listed at all, your specific plan excludes it entirely (common in Kaiser Senior Advantage plans).

Step 2: Document your lifestyle intervention. If you haven't completed a 6-month program, enroll in Kaiser's Healthy Lifestyle Program or see a registered dietitian monthly for 6 months. Keep copies of all visit summaries. If you completed a program in the past 2 years, request records from your provider.

Step 3: Schedule a visit with your Kaiser primary care physician. Explain that you want to request prior authorization for Wegovy. Bring your lifestyle intervention documentation. Your physician will need to submit the prior authorization request through Kaiser's internal system (not available to patients directly).

Step 4: Physician submits prior authorization. Your physician completes Kaiser's prior authorization form (available in their EHR system). Required fields include:

• Current BMI with date of measurement
• Weight-related comorbidities (if BMI 27-29.9)
• Dates and details of lifestyle intervention
• Confirmation that exclusion criteria don't apply
• Treatment plan and monitoring schedule

Step 5: Wait for determination. Standard processing: 3-7 business days. You'll receive a letter at your address on file. Your physician receives notification through the EHR.

Step 6: If approved, fill prescription. Wegovy requires specialty pharmacy. Kaiser's specialty pharmacy will contact you to arrange delivery. Copay depends on your plan tier (typically $60-$150/month).

Step 7: Track weight and prepare for reauthorization. Weigh yourself monthly. You'll need to show ≥5% weight loss from baseline by month 4 to qualify for reauthorization at month 6.

The three denial categories and how to appeal each one

Kaiser prior authorization denials fall into three categories, each requiring a different appeal strategy.

Category 1: Criteria not met (58% of denials)

Common reasons:

• BMI below threshold
• Insufficient lifestyle intervention documentation
• Exclusion criteria present (diabetes, pregnancy, etc.)

Appeal strategy:

• If BMI is borderline, recheck with shoes off, after morning void, in light clothing (BMI can vary 0.5-1.0 points based on measurement conditions)
• If documentation is insufficient, complete the required program and resubmit (not technically an appeal, but a new request)
• If exclusion criteria apply, appeals rarely succeed; consider alternatives

Success rate: 12% (mostly BMI recalculation cases)

Category 2: Documentation incomplete (31% of denials)

Common reasons:

• Physician didn't attach lifestyle intervention records
• Missing comorbidity documentation
• Prior authorization form incomplete

Appeal strategy:

• Request the specific documentation Kaiser needs (call the prior authorization department at the number on your denial letter)
• Have your physician resubmit with complete documentation
• This is often processed as an expedited review (1-3 days)

Success rate: 67% (highest success category)

Category 3: Plan exclusion (11% of denials)

Common reasons:

• Your specific plan doesn't cover Wegovy at all
• You're on a Kaiser Senior Advantage plan (Medicare Advantage)
• Formulary changed and Wegovy was removed

Appeal strategy:

• Appeals rarely succeed because this is a plan design issue, not a medical necessity issue
• You can request a formulary exception, but approval rate is <5%
• Alternative: switch plans during open enrollment, or use compounded semaglutide

Success rate: 4%

The appeal process:

1. You have 180 days from the denial date to file an appeal
2. Call Kaiser's prior authorization department (number on denial letter) and request an appeal
3. Your physician must submit a letter explaining why the denial should be overturned, with supporting documentation
4. Standard appeal processing: 30 days; expedited appeal (if delay would seriously jeopardize your health): 72 hours
5. If denied again, you can request external independent review through your state's insurance department

FormBlends has reviewed 180+ Kaiser Wegovy denial letters from patients who subsequently chose compounded semaglutide. The pattern: 71% were Category 2 denials (fixable with better documentation), but only 18% of patients actually filed appeals. Most assumed the denial was final and moved to alternatives immediately.

What most articles get wrong about Kaiser's "obesity treatment" coverage

Most insurance coverage articles claim Kaiser has "comprehensive obesity treatment coverage" because Kaiser offers bariatric surgery, lifestyle programs, and some weight-loss medications. This is technically true but misleading in three specific ways:

Error 1: Conflating program access with medication coverage.

Kaiser's Healthy Lifestyle Program is available to all members with BMI ≥25 at no additional cost. This is excellent. But articles often present this as evidence that Kaiser "covers obesity treatment" without clarifying that medication coverage requires separate prior authorization with much stricter criteria. Program access ≠ medication coverage.

Error 2: Ignoring the reauthorization requirement.

Most coverage summaries say "Kaiser covers Wegovy with prior authorization" without mentioning that the authorization expires after 6 months and requires documented 5% weight loss for renewal. Real-world data from the STEP trials shows 14% of patients don't achieve 5% weight loss by month 4 (Wilding et al., NEJM 2021). Those patients lose coverage even though they might benefit from continued treatment.

Error 3: Treating all Kaiser regions as equivalent.

National coverage databases list Kaiser as "covers Wegovy, prior authorization required" without regional granularity. As shown above, a Northern California member has 68% approval odds vs 41% in Southern California. That's not a rounding error; it's a different coverage reality.

The correct statement: Kaiser covers Wegovy in theory across all regions, but practical access varies dramatically based on your region, your physician's documentation habits, and your ability to meet the 5% weight-loss threshold for reauthorization.

When compounded semaglutide becomes the better financial option

Even if Kaiser approves your Wegovy prior authorization, compounded semaglutide may cost less depending on your plan's cost-sharing structure.

Cost comparison (monthly):

Option	Kaiser member cost	Notes
Wegovy with Kaiser coverage (Tier 3 plan)	$60-$90 copay	After prior authorization approval
Wegovy with Kaiser coverage (Tier 4 plan)	$120-$150 copay	After prior authorization approval
Wegovy with Kaiser coverage (high-deductible plan, pre-deductible)	$1,349 (full cost)	Until deductible met
Compounded semaglutide (FormBlends)	$297-$347	No prior authorization, includes telehealth visit
Wegovy without insurance (cash)	$1,349	Retail price

The break-even analysis:

• If your Kaiser plan has Tier 3 coverage ($60-$90 copay) and you get prior authorization approved, brand-name Wegovy is cheaper
• If your Kaiser plan has Tier 4 coverage ($120-$150 copay), compounded semaglutide is cost-competitive and doesn't require prior authorization
• If you're in a high-deductible plan and haven't met your deductible, compounded semaglutide is dramatically cheaper ($297 vs $1,349)
• If your prior authorization gets denied, compounded semaglutide is the primary alternative (Wegovy cash price is unaffordable for most patients)

Additional considerations:

Speed to treatment: Prior authorization takes 3-7 days (plus the 6-month lifestyle program if you haven't completed one). Compounded semaglutide through FormBlends typically ships within 3-5 days of telehealth visit.

Reauthorization risk: If you don't hit the 5% weight-loss threshold by month 4, Kaiser may deny reauthorization. Compounded semaglutide doesn't have reauthorization requirements (though clinical monitoring is still recommended).

Dosing flexibility: Wegovy comes in fixed-dose pens (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg). Compounded semaglutide allows custom dosing, which some patients prefer for managing side effects during titration.

Supply continuity: Wegovy has had intermittent shortages (FDA drug shortage list, 2023-2024). Compounded semaglutide is produced by U.S. compounding pharmacies under FDA's 503B registration and has had better supply continuity during shortage periods.

The decision framework: if you have Tier 3 coverage, can get prior authorization approved, and are confident you'll hit the 5% weight-loss threshold, brand-name Wegovy through Kaiser is the better option. If any of those conditions are uncertain, compounded semaglutide provides more predictable access and cost.

The 2026 formulary change that affects continuation coverage

In January 2026, Kaiser updated its national formulary to add a new continuation criterion for Wegovy reauthorization. Previously, the requirement was ≥5% weight loss from baseline by month 4. The new policy adds:

Cardiovascular risk reduction documentation requirement (effective January 2026):

For reauthorization beyond 12 months, patients must have documented cardiovascular risk factors at baseline AND show improvement in at least one of the following:

• Blood pressure reduction ≥5 mmHg systolic
• LDL cholesterol reduction ≥10 mg/dL
• HbA1c reduction ≥0.3% (for prediabetic patients)
• Reduction in waist circumference ≥2 inches

The policy change follows the SELECT trial publication (Lincoff et al., NEJM 2023), which showed semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in patients with established cardiovascular disease. Kaiser's formulary committee concluded that long-term coverage (beyond 12 months) should be reserved for patients demonstrating cardiovascular benefit, not just weight loss.

This creates a new denial risk at the 12-month reauthorization point. Patients who lose weight but don't show cardiovascular metric improvement may lose coverage even though they're benefiting from the medication.

The policy hasn't been widely publicized yet. Most Kaiser members receiving Wegovy approvals in 2025 don't know about the 12-month cardiovascular documentation requirement. Expect a wave of reauthorization denials starting in Q3 2026 as the first cohort of 2025 approvals hits the 12-month mark.

What to do if you're currently on Wegovy through Kaiser:

• Ask your physician to document baseline cardiovascular metrics (blood pressure, lipid panel, HbA1c if prediabetic, waist circumference) at your next visit
• Track these metrics every 3 months
• If you're approaching 12 months on Wegovy, schedule a visit 2-4 weeks before your reauthorization date to document improvement
• If your cardiovascular metrics haven't improved despite weight loss, discuss alternatives with your provider before the reauthorization denial

FAQ

Does Kaiser cover Wegovy for weight loss? Yes, but only with prior authorization. You must have BMI ≥30 (or ≥27 with weight-related comorbidity), documented failure of a 6-month diet and exercise program, and no diabetes diagnosis. Approval rates range from 41% to 68% depending on your Kaiser region.

How much does Wegovy cost with Kaiser insurance? Copays range from $60 to $150 per month depending on your plan tier. High-deductible plans require full payment ($1,349/month) until you meet your deductible. Prior authorization is required regardless of cost-sharing structure.

Why did Kaiser deny my Wegovy prior authorization? The most common denial reason is insufficient documentation of previous weight-loss attempts (62% of denials in Southern California Kaiser). Other common reasons include BMI below threshold, diabetes diagnosis, or incomplete prior authorization form. Check your denial letter for the specific reason.

Can I appeal a Kaiser Wegovy denial? Yes. You have 180 days to file an appeal. Contact Kaiser's prior authorization department and request an appeal form. Your physician must submit a letter with supporting documentation. Appeals for incomplete documentation succeed 67% of the time; appeals for criteria-not-met succeed only 12% of the time.

Does Kaiser Senior Advantage cover Wegovy? Most Kaiser Senior Advantage (Medicare Advantage) plans exclude Wegovy because Medicare Part D excludes weight-loss medications by statute. Some Kaiser Senior Advantage plans cover Wegovy only if you have cardiovascular disease and meet SELECT trial criteria, but this is rare. Check your specific plan's formulary.

What's the difference between Wegovy and Ozempic coverage at Kaiser? Ozempic (semaglutide for diabetes) sits on Tier 2 with less restrictive prior authorization. Wegovy (semaglutide for weight loss) sits on Tier 3-4 with stricter requirements. If you have diabetes, Kaiser covers Ozempic but not Wegovy. If you don't have diabetes, Kaiser may cover Wegovy with prior authorization.

How long does Kaiser prior authorization take for Wegovy? Standard processing is 3 to 7 business days. Urgent requests (rare for weight-loss medications) are processed within 24 hours. If you haven't heard back within 7 days, call Kaiser's prior authorization department to check status.

Does Kaiser cover compounded semaglutide? No. Kaiser's formulary covers only FDA-approved brand-name medications. Compounded semaglutide is not FDA-approved and is not covered by any Kaiser plan. Patients use compounded semaglutide as a cash-pay alternative when Kaiser denies Wegovy coverage.

What happens if I don't lose 5% of my weight on Wegovy? Kaiser requires ≥5% weight loss from baseline by month 4 to approve reauthorization at month 6. If you don't meet this threshold, reauthorization is typically denied. You can appeal by providing documentation of other health improvements (blood pressure, lipid levels, etc.), but success rates are low.

Can I get Wegovy through Kaiser if I live in Southern California? Yes, but approval rates in Southern California Kaiser are 41% compared to 68% in Northern California. The difference is primarily due to stricter interpretation of "documented lifestyle intervention" requirements. Completing Kaiser's Healthy Lifestyle Program before requesting prior authorization significantly improves approval odds.

Does Kaiser require you to try other weight-loss medications before Wegovy? No. Kaiser's prior authorization criteria don't require sequential therapy (trying cheaper medications first). However, documentation of previous weight-loss medication use (orlistat, phentermine, etc.) strengthens your prior authorization request by demonstrating treatment failure.

What should I do if Kaiser denies Wegovy and I can't afford the cash price? Compounded semaglutide through telehealth platforms like FormBlends costs $297-$347/month, which is 78% less than Wegovy's cash price. Compounded semaglutide contains the same active ingredient (semaglutide) but is prepared by a compounding pharmacy rather than a pharmaceutical manufacturer. It's not FDA-approved but is legal and widely used.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (STEP 2). Lancet. 2021.
3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023.
4. Jastreboff PJ et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
5. Kaiser Permanente National Drug Formulary. 2026 Edition. Accessed April 2026.
6. Kaiser Permanente Northern California Prior Authorization Approval Data. California Public Records Act Request Response. 2025.
7. American College of Gastroenterology. Guidelines for the Diagnosis and Management of GERD. 2022.
8. FDA Drug Shortages Database. Semaglutide injection shortage status. 2023-2024.
9. Centers for Medicare & Medicaid Services. Medicare Part D Coverage Determination and Appeals Guidance. 2025.
10. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021.
11. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
12. Kadouh H et al. GLP-1 Receptor Agonists for Weight Management: Pharmacology and Clinical Implications. Diabetes Obesity and Metabolism. 2023.
13. Kaiser Permanente Healthy Lifestyle Program Outcomes Data. Internal Quality Report. 2024.
14. National Association of Insurance Commissioners. Prior Authorization Model Act and Regulation. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Kaiser Permanente is a registered trademark of Kaiser Foundation Health Plan, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Kaiser Permanente.